



09-03-02


0300

#f

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" mailing label number EV103966492US
Date of Mailing: August 30, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Services, utilizing the "Express Mail" Post Office to Addressee" service addressed to **Assistant Commissioner for Patents, Washington, DC 20231** and mailed on the above Date of Mailing with the above "Express Mail" mailing label number.


Tracy L. Morton

(Signature)

Signature Date: August 30, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)
)
Inventor(s): Roger Williams et al.)
)
SC/Serial No: 09/974,573)
)
Filed: October 9, 2001)
)
Title: Phosphoinositide 3-Kinases)
)

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed May 17, 2002, enclosed are the following documents:

Copy of Notice.
 Sequence Listing in both CRF and Paper Copy.

10/02/2002 YGIZAW 0000003 150615 09974573

01 FC:116 400.00 CH


The content of the paper and computer readable copies are the same and, include no new matter.

The Commissioner is hereby authorized to charge all fees associated with this communication to Deposit Account #15-0615, including extension of time fees that may be due. A duplicate copy of this authorization is enclosed.

Date: August 30, 2002

By: Gregory Giotta
Gregory Giotta
Reg. No. 32,028

ONYX PHARMACEUTICALS, INC.
3031 Research Drive
Richmond, CA 94806
Telephone: 510-262-8710
Facsimile: 510-222-9758



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/974,573	10/09/2001	Roger Williams	ONYX1048.ORD

Gregory Giotta, Ph.D.
 Vice President and Chief Legal Counsel
 ONYX Pharmaceuticals, Inc.
 3031 Research Drive
 Richmond, CA 94806

CONFIRMATION NO. 8292
FORMALITIES LETTER



OC000000008149757

Date Mailed: 05/17/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

files

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART I - ATTORNEY/APPLICANT COPY